Showing results (31-40 of 90) with videos related to

Sort By:
Pageof 9
Transplantation and Cellular Therapy|May 4, 2026
Third-Party Viral Specific T cells for Immunocompromised Hosts and Access Barriers: A Review and Commentary by an Expert Panel from ASTCTStella M Davies, Emily Blyth, Catherine M Bollard, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 20, 2014
Frequent human herpesvirus-6 viremia but low incidence of encephalitis in double-unit cord blood recipients transplanted without antithymocyte globulinAmanda L Olson, Parastoo B Dahi, Junting Zheng, et al.
Blood Advances|July 3, 2020
DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortalityKitsada Wudhikarn, Martina Pennisi, Marta Garcia-Recio, et al.
Leukemia & Lymphoma|March 29, 2021
Outcomes of adult T-Cell leukemia/lymphoma with allogeneic stem cell transplantation: single-institution experienceZachary D Epstein-Peterson, Nivetha Ganesan, Juliet N Barker, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 27, 2020
Prognostic Factors for Postrelapse Survival after ex Vivo CD34+-Selected (T Cell-Depleted) Allogeneic Hematopoietic Cell Transplantation in Multiple MyelomaAlexandra Gomez-Arteaga, Gunjan L Shah, Raymond E Baser, et al.
Blood Advances|January 5, 2019
Burden and impact of multifactorial geriatric syndromes in allogeneic hematopoietic cell transplantation for older adultsRichard J Lin, Patrick D Hilden, Theresa A Elko, et al.
Blood Advances|June 21, 2021
Toxicities of high-dose chemotherapy and autologous hematopoietic cell transplantation in older patients with lymphomaParastoo B Dahi, Jasme Lee, Sean M Devlin, et al.
Blood Cancer Journal|August 8, 2020
Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphomaKitsada Wudhikarn, M Lia Palomba, Martina Pennisi, et al.
Transplantation and Cellular Therapy|November 30, 2025
Outcomes of Terminal Complement Blockade in Adults with High-Risk Transplant-Associated Thrombotic Microangiopathy: A Comparative AnalysisMohammad Alhomoud, Glenn Heller, Christina Cho, et al.
Blood Advances|October 21, 2021
Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysisMehdi Hamadani, Ajay K Gopal, Marcelo Pasquini, et al.
Pageof 9